Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Watkins v. Solid Biosciences, Inc. et al
Case Number:
1:18-cv-10587
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
May 30, 2018
Investors Spar For Lead In Mass. Bioscience Class Action
One investor backed by Glancy Prongay & Murray LLP is competing with another represented by Levi & Korsinsky LLP in separate bids filed in Massachusetts federal court Tuesday to be named lead plaintiff in a proposed class action accusing a bioscience company of withholding information about the toxicity of its signature muscular dystrophy treatment ahead of its initial public offering.
-
March 28, 2018
Biz Misled On Gene Therapy Toxicity Pre-IPO, Investors Say
Solid Biosciences Inc. has been accused of securities fraud in a Massachusetts federal lawsuit filed Tuesday by a putative class of investors who claim the company was not forthcoming about the toxicity of its signature muscular dystrophy treatment ahead of its initial public offering, leading to stock drops once its risks were revealed.